Ajay K Chaudhary
Research Affiliate, Centre for Genetics and Pharmacology (CGP), Roswell Park Cancer Institute (RPCI)
Elm & Carlton Street Buffalo, New York, USA
Ajay Chaudhary obtained his Ph.D. Biotechnology from University of Allahabad, India. During doctoral research program, he extensively worked on Pathogenesis of Matrix Metalloproteinase (MMPs) and Human Papilloma virus (HPV) in Head and Neck Cancer. During doctoral research work, he developed multiplex PCR technology to detect high risk HPV in oral cancer. After PhD, he joined as Research Associate at Translational Research laboratory, Advance Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Hospital, India and awarded prestigious Indian Council of Medical Research Post-Doctoral Fellowship. He did his PDF research work at the National Institute of Immunohematology (NIIH), King Edward Memorial Hospital, Mumbai, India. At present he works as Research Affiliate at Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute (RPCI), New York, United State of America. His expertise is in the area of molecular and cellular biology with particular reference to molecular & cellular mechanism and mitochondrial dysfunctions in prostate cancer. The current research focuses of Dr. Chaudhary are on investigating the effects of chemotherapeutics agents on mitochondrial functions and dysfunctions against variety of cancer. Dr. Chaudhary’s work is also focused on the effect of different chemo preventive and natural compounds on extrinsic and intrinsic pathways of mitochondrial which associates with programmed cell death/apoptotic pathways. He has published over 22 International scientific publications, 12 abstract indexed in different National & International conferences. He appointed as potential reviewer and editorial board member of various reputed journal.
Study on mitochondrial dysfunction, apoptosis, cell cycle analysis, cell death receptor, cancer signaling pathways, role of heat-shock proteins in cancer cell survival and death, and Inhibition of matrix metalloproteinase, for the development of novel cancer therapeutics markers.